国联民生证券承销保荐有限公司 关于上海优宁维生物科技股份有限公司 部分募投项目延期的核查意见 国联民生证券承销保荐有限公司（以下简称"保荐机构"）作为上海优宁维 生物科技股份有限公司（以下简称"优宁维"或"公司"）首次公开发行股票并 在创业板上市及持续督导的保荐机构，根据《证券发行上市保荐业务管理办法》、 《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作》、《上市公司募集资金监管规则》等 有关法律法规和规范性文件的规定，对优宁维部分募投项目延期的情况进行了审 慎核查，核查的具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意上海优宁维生物科技股份有限 公司首次公开发行股票注册的批复》（证监许可〔2021〕3556 号）同意注册， 并经深圳证券交易所同意，优宁维首次公开发行人民币普通股（A 股）股票 2,166.6668 万股，每股面值为人民币 1.00 元，发行价格为人民币 86.06 元/股，募 集资金总额为人民币 186,463.34 万元，扣除发行费用人民币 26,911.62 万元（不 含税）后，实际募集资金净额 ...

根据《首次公开发行股票并在创业板上市招股说明书》，公司首次公开发行 股票募集资金扣除发行费用后将投资以下项目： 单位：万元 国联民生证券承销保荐有限公司 关于上海优宁维生物科技股份有限公司部分募投项目 结项并将节余募集资金永久补充流动资金的核查意见 国联民生证券承销保荐有限公司（以下简称"保荐机构"）作为上海优宁维 生物科技股份有限公司（以下简称"优宁维"或"公司"）首次公开发行股票并 在创业板上市及持续督导的保荐机构，根据《证券发行上市保荐业务管理办法》、 《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》、《上市公司募集资金监管规则》等有关 法律法规和规范性文件的规定，对优宁维部分募投项目结项并将节余募集资金永 久补充流动资金的情况进行了审慎核查，核查的具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意上海优宁维生物科技股份有限 公司首次公开发行股票注册的批复》（证监许可〔2021〕3556 号）同意注册， 并经深圳证券交易所同意，优宁维首次公开发行人民币普通股（A 股）股票 2,166.6668 万股，每股面值为 ...

证券日报网讯12月30日，优宁维（301166）在互动平台回答投资者提问时表示，公司客户主要为国内高 等院校、科研院所、医院和生物医药企业等。随着公司自主品牌产品持续丰富、海外市场的持续拓展， 公司期待为包括辉瑞制药及默沙东在内的生物医药头部企业提供相关产品和服务。 ...

证券日报网讯12月30日，优宁维（301166）在互动平台回答投资者提问时表示，公司第三方品牌产品主 要面向国内高等院校、科研院所、医院和生物医药企业等科研端，不同于用于临床的医疗器械。 ...

优宁维（301166.SZ）12月30日在投资者互动平台表示，公司第三方品牌产品主要面向国内高等院校、 科研院所、医院和生物医药企业等科研端，不同于用于临床的医疗器械。 每经AI快讯，有投资者在投资者互动平台提问：公司代理的产品有没有入选医保目录？ （记者 胡玲） ...

Core Viewpoint - The company, Youningwei (301166), emphasizes its commitment to the Yangtze River Delta region as a vital area for economic development and its strategic importance for the company's operations [1] Group 1: Company Operations - The company is headquartered in Shanghai, the central city of the Yangtze River Delta, and has subsidiaries and offices in Nanjing, Hangzhou, and Hefei [1] - To better serve clients nationwide, the company has established a protein research and development center and a self-branded R&D production base in Nanjing, as well as an antibody research center in Hangzhou [1] - The Yangtze River Delta has become one of the company's most important business regions due to continuous resource investment and deepening of business operations [1] Group 2: Future Plans - The company plans to continue focusing on the Yangtze River Delta region, leveraging local talent, location advantages, and industrial clusters to meet customer demands [1] - The goal is to provide higher quality products and services to all clients, including those in the Yangtze River Delta [1]

Group 1 - The company has established an online and offline dual-channel sales model for its products in the pharmaceutical e-commerce sector [2] - Online sales are primarily conducted through the company's own mall, WeChat, Douyin, and third-party professional service websites to enhance product visibility [2] - For overseas markets, the company is expanding through overseas e-commerce platforms and participation in international trade shows [2]

Core Viewpoint - The company, Uningwei (301166), is focused on its one-stop platform strategy and antibody strategy, aiming to find relevant target companies in the upstream and downstream application fields of antibodies for synergistic development with its existing business [1] Group 1 - The company emphasizes strict compliance with information disclosure regulations and will announce any substantial progress or transactions that meet disclosure standards in a timely manner [1]

证券日报网讯 12月25日，优宁维在互动平台回答投资者提问时表示，公司作为全国布局的生命科学一 站式服务商，已在海口等全国各地设有18个办事处及11个子公司。未来公司将会根据业务开展情况，综 合考虑优化业务布局，借助相关地区的政策优势加快业务发展。 （编辑 任世碧） ...

Group 1 - The core viewpoint of the news is that You Ning Wei's stock performance and financing activities indicate a high level of investor interest, despite a decline in revenue and profit [1][2]. - As of December 24, You Ning Wei's stock price increased by 0.60%, with a trading volume of 17.13 million yuan, and a net financing purchase of 287,600 yuan [1]. - The total financing and securities balance for You Ning Wei reached 63.36 million yuan, accounting for 2.44% of its market capitalization, which is above the 90th percentile of the past year [1]. Group 2 - As of September 30, the number of shareholders for You Ning Wei decreased by 13.19% to 9,893, while the average circulating shares per person increased by 15.19% to 5,753 shares [2]. - For the period from January to September 2025, You Ning Wei reported a revenue of 776 million yuan, a year-on-year decrease of 6.24%, and a net profit attributable to shareholders of -15.08 million yuan, a decline of 207.11% [2]. - Since its A-share listing, You Ning Wei has distributed a total of 182 million yuan in dividends, with 138 million yuan distributed in the last three years [3].